Effects of a Phytoestrogen Intervention and Estrogen Receptor β Genotype on Prostate Cancer Proliferation and PSA Concentrations—A Randomized Controlled Trial
Journal article, 2025

A phytoestrogen-rich diet has been suggested to reduce tumor proliferation among men with prostate cancer, and the effect may differ between men with different polymorphisms of the estrogen receptor‐beta gene (ERβ). Patients with low- or intermediate-risk prostate cancer scheduled for radical prostatectomy were randomized to an intervention group (n = 71) provided with soybeans and flaxseeds (∼200 mg phytoestrogens/day) to eat until surgery (approximately 6 wk) or to a control group (n = 69). Tumor proliferation was assessed using Ki-67 indexes, prostate-specific antigen (PSA) concentrations were analyzed in blood, and ERβ polymorphism was genotyped in all subjects. The intervention group had a 13% unit lower risk [95% confidence interval (CI): −28%, 1.8%] of a higher Ki-67 index compared to controls, but the effect was most pronounced among TT carriers of ERβ [risk difference (RD) −19%, 95% CI: −45%, 6.8%]. Subjects with genotype TC/CC had a lower risk (RD −29%, 95% CI: −46%, −1.2%) and TT genotype a higher risk (RD 25%, 95% CI: 8.7%, 42%) of increased PSA concentration, comparing the intervention group to controls. In conclusion, a phytoestrogen-rich diet may cause lower tumor proliferation and concentration of PSA in men with prostate cancer with a specific genetic upset of ERβ.

Author

Rebecca Ahlin

Sahlgrenska University Hospital

University of Gothenburg

Andreas Josefsson

University of Gothenburg

Umeå University

Sanna Nybacka

University of Gothenburg

Rikard Landberg

Chalmers, Life Sciences, Food and Nutrition Science

Johan Stranne

Sahlgrenska University Hospital

University of Gothenburg

Gunnar Steineck

University of Gothenburg

M. Hedelin

University of Gothenburg

Karolinska Institutet

Nutrition and Cancer

0163-5581 (ISSN) 1532-7914 (eISSN)

Vol. 77 1 124-138

Subject Categories

Urology and Nephrology

Cancer and Oncology

DOI

10.1080/01635581.2024.2407007

PubMed

39340410

More information

Latest update

12/16/2024